分子バイオマーカーと診断のジャーナル

Drug-Resistant Neuroblastoma Expression of Immunomodulatory Checkpoint Molecules

Abstract

Stephen Szajek*

Neuroblastoma is a cancer that arises from developing nerve cells in infants and young children. It is the most common extracranial solid tumor of childhood, accounting for 6% to 10% of all childhood cancers. Despite advances in treatment, high-risk neuroblastoma remains a challenging disease to cure. One of the reasons for this is the development of drug-resistant neuroblastoma, which is a major obstacle in the successful treatment of this disease. In recent years, researchers have begun to investigate the expression of immunomodulatory checkpoint molecules in drug-resistant neuroblastoma cells as a potential target for new therapies.